摘要
急性髓系自血病细胞群是由不同分化阶段的自血病细胞组成，其中最原始的细胞为自血病干细胞（LSC）。与相对分化的自血病细胞相比，LSC主要处于G0期，其对常规化疗药物无效，因此LSC是自血病复发的根源。将近年来对LSC的细胞和分子生物学及靶向治疗方面研究的进展进行综述，为自血病发病机制及治疗策略的探讨提供新的思路。
Acute myelogenous leukemia （AML） cells are organized in a hierarchical fashion, with only the most primitive rare population （leukemia stem cell, LSC） of AML cells capable of maintaining the leukemic clone. Due to a predominantly Go cell-cycle status, LSC may not be responsive to conventional chemotherapeutic agents,compared with leukemia blasts. It is proposed that surviving LSC are a major contributing factor to leukemia relapse. This article reviewed the data emerging from the study of LSC, elucidated the distinct cellular and molecular characteristics of the LSC population,and the target therapy of LSC, which may shed new light on AML therapy and leukemogenesis study.
出处
《白血病．淋巴瘤》
CAS
2008年第3期228-230,共3页
Journal of Leukemia & Lymphoma
基金
国家自然科学基金（30672746）
关键词
自血病
干细胞
治疗
Leukemia
Stem cells
Therapy
